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Abstract Immune-deficient mouse models of liver damage
allow examination of human stem cell migration to sites of
damage and subsequent contribution to repair and survival.
In our studies, in the absence of a selective advantage,
transplanted human stem cells from adult sources did not
robustly become hepatocytes, although some level of fusion
or hepatic differentiation was documented. However,
injected stem cells did home to the injured liver tissue and
release paracrine factors that hastened endogenous repair
and enhanced survival. There were significantly higher
levels of survival in mice with a toxic liver insult that had
been transplanted with human stem cells but not in those
transplanted with committed progenitors. Transplantation of
autologous adult stem cells without conditioning is a
relatively safe therapy. Adult stem cells are known to
secrete bioactive factors that suppress the local immune
system, inhibit fibrosis (scar formation) and apoptosis,
enhance angiogenesis, and stimulate recruitment, retention,
mitosis, and differentiation of tissue-residing stem cells.
These paracrine effects are distinct from the direct
differentiation of stem cells to repair tissue. In patients at
high risk while waiting for a liver transplant, autologous
stem cell therapy could be considered, as it could delay the
decline in liver function.
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Abbreviations
AAT α-1-antitrypsin
ALB albumin
ALDH aldehyde dehydrogenase
ALDH
hi high activity of ALDH
ALDH
lo low activity of ALDH
BMSC bone marrow stem cell
CCl4 carbon tetrachloride
DAPI 4,6-diaminidino-2-phenylindole
FACS fluorescence-activated cell sorting
FAH fumarylacetoacetate hydrolase
FISH fluorescent in situ hybridization
GUSB beta-glucuronidase
hCBSC human cord blood stem cells
HNF1 hepatocyte nuclear factor 1
Lin
− lineage-depleted
MPS VII mucopolysaccharidosis type VII
NOD/
SCID
nonobese diabetic/severe combined immuno-
deficient
Tissue-dependent fusion and stem-cell-induced repair
of nonhematopoietic tissues including the liver
“Plasticity” refers to the putative ability of adult stem cells
to acquire mature cell phenotypes distinct from their tissue
of origin. Reports had initially described that transplanted
bone marrow (BM)-derived stem cells could generate cells
with unexpected phenotypes, including cardiac and skeletal
muscle, brain, endothelial, endocrine, and epithelial line-
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e-mail: jan.nolta@ucdmc.ucdavis.eduages, in addition to liver (reviewed in [1, 2]). These
phenomena occurred at a low frequency in vivo [3] and
required tissue damage for stem cell recruitment and
selective survival advantage for propagation [4]. Several
reports then failed to reproduce original findings [5–7] but
other studies demonstrated that transplanted BM cells
engrafted nonhematopoietic tissues and stimulated im-
proved function of the damaged organs in vivo [4, 8–10].
The biological mechanisms responsible for “stem cell
plasticity” are still debated, especially in the liver. Recent
studies have shown stem cell fusion with mature tissue-
specific cells [11–13]. Fusion of transplanted BM-derived
cells with damaged cells has been implicated in the
production of skeletal muscle [14], neural [15], cardiac
[6], and hepatic cells [12, 13, 16]. Cre-recombinase-
mediated activation of reporter genes has been used to
detect cell fusion events after bone marrow transplantation
in vivo. Alvarez-Dolado et al. used this system to
demonstrate donor bone-marrow-derived cell fusion with
mature recipient hepatocytes, cardiomyocytes, and Purkinje
cells [15]. Two other groups have used similar Cre-loxP
strategies to show the absence of cell fusion [17, 18]. Ianus
et al. [17] used Y chromosome fluorescent in situ
hybridization (FISH), in combination with an insulin-
promoter-driven Cre/Lox system, to show the production
of BM-derived insulin-producing cells without Cre-
mediated activation of enhanced green fluorescence protein
through cell fusion. We have shown that, although
relatively rare, cell fusion does exist in vivo between
transplanted human stem cells and recipient immune-
deficient mouse hepatocytes, resulting in human albumin-
expressing cells [19]. However, Harris et al. identified
epithelial cells in the lung, skin, and liver that develop from
BM-derived cells through a mechanism other than cell
fusion [18]. Cell fusion may be a cell-type-specific
phenomenon that is more common in organs that normally
contain cells with different ploidies such as liver and
muscle and can be induced by acute physiologic injury. In
addition, it seems probable that alternate mechanisms, such
as the induction of angiogenic processes [20] and stem-cell-
mediated enhancement of cellular proliferation [10], are
involved in the cumulative benefit of stem-cell-mediated
repair of nonhematopoietic organs.
Liver transplantation remains the only therapeutic option
for many acute and chronic end-stage liver diseases.
However, this approach is limited by a serious shortage of
donor organs required for transplantation. A number of
studies have suggested that stem cells from bone marrow
could generate hepatocytes (reviewed in [21]). The most
successful liver repopulation with bone-marrow-derived
cells was observed in mice with fumarylacetoacetate
hydrolase (FAH−/−) deficiency resulting in functional
correction of the liver disease [4, 12, 13]. In this excellent
model, there is a strong selection for corrected donor
hepatocytes that express the functional enzyme, in contrast
to other liver damage models where the endogenous
recipient cells can also contribute to the repair. In the
xenotransplantation models with human cells injected into
mice, the contribution from the donor human cells to the
damaged liver can be easily observed by human-specific
markers or centromeric chromosome analysis by FISH that
discriminate between murine and human chromosomes
(Fig. 1)[ 22, 23].
Isolation of hematopoietic stem cells for liver repair
using phenotypic vs. functional markers
Methods to identify the most primitive hematopoietic stem
cells (HSC) are constantly sought. The CD34 protein is
frequently used as a marker for positive selection of human
hematopoietic stem and progenitor cells. However, Goodell
et al. [24, 25] characterized murine Hoechst dye-excluding
side population cells that lacked CD34 expression and had
reconstitution capacity. Bhatia et al. [26] demonstrated a
low level of engraftment activity in human CD34- cells. We
showed that highly purified human CD34+ cells generated
CD34− cells in immune-deficient mice after 1 year and that
the reisolated human CD34− cells retained the capacity to
regenerate CD34+ cells upon secondary transplantation. We
determined that CD34 expression at the cell surface and
messenger RNA (mRNA) level can be turned on and off,
relating to the quiescence of the human hematopoietic stem
Fig. 1 FISH analysis for human and mouse centromeres in liver
sections. Liver sections from a mouse that had been transplanted with
ALDH
hiLin
− cells after CCL4-mediated liver injury were probed with
both human (red dots in nuclei) and mouse (green dots in nuclei)
centromeric probes. The analysis shows that the liver was heavily
engrafted with human stem cells and that the majority of the human
cells had not undergone fusion with the damaged murine hepatocytes
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engraft in beige/nude/xid immune-deficient mice and their
progeny can be recovered from the murine bone marrow for
as long as 18 months posttransplantation [28, 29]. When
reisolated from the marrow of beige/nude/xid mice, the
human cells were absolutely devoid of CD34 expression.
No CD34 mRNA was detected in the human CD45+ cells,
reisolated from the bnx bone marrow. The human CD45+/
CD34− cells generated multilineage reconstitution in
secondary nonobese diabetic/severe combined immunode-
ficient (NOD/SCID) recipients. CD34+ cells were recov-
ered from the secondary recipients, demonstrating that
CD34 expression is reversible: CD45+/CD34+/CD38−
cells can generate CD45+/CD34− cells, which can then
generate CD45+/CD34+ cells. Our data agree with reports
from Makio Ogawa’s group [30], which indicate that CD34
expression may be an activation-dependent event. Hess and
Bhatia had independently found that after coculture and
transplantation into immune-deficient mice, male CD34-/
Lin- cells generated CD34+/CD38− cells, which, upon
recovery from the mice, demonstrated clonogenic progen-
itor function into multiple lineages [31]. These data
demonstrated that expression of CD34 is reversible on
human multilineage engrafting stem/progenitor cells [27,
32]. This calls for different purification strategies, based on
conserved stem cell function as well as phenotype, to avoid
“missing” the most primitive or multipotent cells within the
bone marrow.
Since we and others have shown that human hemato-
poietic cell phenotype can vary with activation state [27,
30, 31, 33], we therefore sought a functional rather than
phenotypic method for identifying human stem cells with
regenerative potential. The use of metabolic markers such
as rhodamine and Hoechst 33342 dye efflux separates cells
based on high expression of membrane pumps encoded by
the multiple drug resistance genes, a characteristic believed
to be associated with very immature stem/progenitor cells
[24, 25, 34, 35]. Another very interesting metabolic marker
indicative of early immature cells is the enzyme aldehyde
dehydrogenase (ALDH), shown by our group and others to
correlate with high stem cell activity in vivo [36–38]. In our
studies, progenitor function and reconstituting ability were
exclusive to the ALDH high and lineage-depleted fraction
(ALDH
hiLin
−), as opposed to the ALDH
loLin
− population
[38]. We also examined the combination of ALDH activity
with markers such as CD133, the human homolog of
prominin 5-transmembrane glycoproteins, which is also a
prominent HSC marker [38–43]. Fractionation of human
HSC based on high ALDH activity, with and without other
markers such as CD133, provided a rigorous selection of
purified stem and progenitor cells [38, 44]. We have
subsequently shown that ALDH
hiLin
− cells represent a
unique mixed stem cell population with hematopoietic,
mesenchymal, and endothelial progenitor function [45] and
have examined the function of this population in tissue
repair, including the liver, as described further below.
Role of hepatocyte growth factor in stem cell survival,
recruitment, and tissue repair
Hepatocyte growth factor (HGF)/scatter factor is a
mesenchymal-derived heparin-binding glycoprotein that
has effects on the survival, mitosis, and migration of many
cell types. HGF induces gradient-directed migration (che-
motaxis) and invasion through extracellular matrix proteins.
It induces a program of activities in migrating cells that are
required for invasion into tissues [46–48]. The mature
molecule is an αB heterodimer that is cleaved from a single
polypeptide precursor. When expressed from vectors in
mammalian cells, the precursor protein is appropriately
cleaved to form the active heterodimer [49, 50]. The
receptor for HGF is the transmembrane tyrosine kinase c-
Met [51]. Both HGF activation and c-Met expression are
inducible by hypoxia. In addition to its established role in
stimulation of hepatocyte survival, migration, and division,
HGF has been found to play a role in hematopoiesis. The
HGF protein is produced by marrow stromal cells, which
suggests that it may have a role in the maintenance of
HSC. c-Met is expressed on hematopoietic progenitors that
respond to HGF [52–60] as well as cells that are capable of
regenerating liver and muscle, in its better known roles
(reviewed in [61]). c-Met is expressed on immature human
marrow-derived hematopoietic stem/progenitor cells with the
phenotype CD34+CD33− and CD34+CD38− but not on
more mature progenitors with the phenotype CD34+CD33+
and CD34+CD38+ [59].
HGF also plays an important role in tissue repair. During
regeneration, expression of HGF from the damaged tissue is
upregulated and later downregulated in controlled patterns
[62, 63]. The role of HGF in repair has been well
documented in the liver. Kupffer cells in the liver
upregulate HGF mRNA following liver injury, and expres-
sion of HGF by endothelial cells in local capillary beds is
also induced [64, 65]. HGF is also upregulated by the
mouse heart in response to myocardial ischemia, and, after
myocardial infarction in humans, HGF secretion was also
upregulated from the infarcted region [66, 67]. HGF also
stimulates the activation and early division of adult satellite
cells in muscle tissue and is present in injured skeletal
muscle [68]. HGF levels are systemically elevated in the
serum of patients with liver failure, supporting the idea that
the liver may be attempting to recruit stem cells to assist
with its repair and regeneration. To gain a better under-
standing of the role of stem cells in liver and muscle repair,
we have examined how these cells might be recruited to
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cells receive after tissue injury may be the hypoxia-induced
local activation of HGF, which could act in a gradient-
dependent manner, to induce stem cell migration into the
damaged tissue and to contribute to repair and survival of
stem/progenitor cells at the site of damage.
Effects of hypoxia at sites of tissue damage on stem cell
phenotype and migration
Recent characterization of the BM microenvironment has
shown that the most primitive hematopoietic stem cells are
distributed along an oxygen gradient. Primitive stem cells
reside in the most hypoxic areas of the BM where low O2
levels enhance the survival and expansion of primitive self-
renewing HSC and endothelial progenitors [69, 70].
Differentiating progenitors reside predominantly in the
more vascular sinuses. Progenitor cell trafficking is con-
trolled by chemokine-mediated interactions to regulate the
development and release of mature cells into the periphery
[71]. CXCR4 and c-Met have both been reported to be
expressed on bone marrow-derived HSC and we demon-
strated that they can both be increased in hypoxic cultures
[72]. CXCR4 has recently been reported to be present as a
cytosolic protein pool in addition to its surface expression,
raising the intriguing question of whether changes in the
microenvironment, such as hypoxia or HGF administration,
could enhance the delivery of the cytosolic protein to the
extracellular surface. c-Met, the receptor for HGF, is rapidly
internalized and degraded following ligand binding. There
is evidence from our laboratory and others to show that
hypoxia enhances not only the expression of c-Met but also
its protein stability and signaling to downstream prosurvival
factors [72, 73].
Following chemical-induced liver injury, such as in the
CCL4 model that we have reported, damage to the proximal
capillaries is a major outcome. The immediate microenvi-
ronment surrounding these capillaries will thus be hypoxic.
This local hypoxia may induce an upregulation in the active
levels of local chemoattractants and growth factors such as
HGF and stromal-derived factor 1 in the damaged region of
tissue. This combination of low oxygen tension and high
chemoattractant gradient may promote the recruitment of
tissue- repairing stem cells to the damaged liver site. The
fact that marrow-derived stem cells can be found at sites of
liver injury (Fig. 2) suggests that they can be recruited to
the hypoxic region and that they can survive in the
damaged microenvironment. This suggests that stem cells
might adapt a phenotype that allows survival in a hypoxic
environment, perhaps induced by HGF, a known survival
factor for multiple stem cell types.
To explore this theory, we set up an immune-deficient
mouse model of liver damage and recovery and determined
that CCL4 allowed better human cell engraftment and
induction of human albumin expression than radiation or
allyl alcohol damage. We transplanted CD34+ or CD34+/
CD38−/CD7− purified hematopoietic stem cells from
human BM and umbilical cord blood (UCB). CD34+/
CD38− cells have been previously defined to be highly
quiescent [74–77], and CD34+/CD38−/CD7− cells are a
subset of this progenitor pool, shown to generate both
lymphoid and myeloerythroid progeny [78]. There was no
albumin expression in this population prior to transplanta-
tion into the mice [79]. Two months after transplantation
into noninjured mice, human hematopoietic cells were
present in the murine livers, but none expressed human
albumin. However, when CCl4 was administered 1 month
after human stem cell transplantation, the human stem cells
were induced to begin expressing human albumin [79]. We
Fig. 2 MPSVII liver. Engraftment of human ALDH
hiLin
− cells into
mouse livers. Representative frozen section slides from the livers of
mice transplanted with human cord blood ALDH
loLin
− (left)o r
ALDH
hiLin
− cells (right). Liver sections were stained for β-
glucuronidase (red) and counterstained for methyl green (green nuclei)
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transplantation of HGF-expressing mesenchymal stem
cells/marrow stromal cells (MSC), using techniques that
we had previously described to produce sustained systemic
levels of specific growth factors from the engineered cells
[80–82]. HGF production from the engineered MSC
accelerated and increased the development of human
albumin-expressing cells, which could be detected as early
as 5 days after the liver injury in some cases [79]. We did
not know at that point whether the hepatocyte-like human
albumin-producing cells arose via differentiation or fusion,
and determining this was a goal of our subsequent studies.
Tissue localization of transplanted human stem cells in
immune-deficient mice
We have studied the in vivo localization of transplanted
ALDH
hiLin
− cells, as well as adipose and marrow-derived
MSC subpopulations, into specific tissues of immune-
deficient mice, during steady state vs. chronic and acute
injury in tissues including liver. In these studies, we are
specifically seeking populations of human cells that cannot
only home into the injured murine tissues but those that
could also mediate repair in a robust manner. These studies
were greatly facilitated by the use of a new mouse model,
the NOD/SCID/mucopolysaccharidosis type VII (MPSVII)
strain developed by Dr. M. Sands [83]. MPSVII is a
lysosomal storage disease caused by a deficiency in B-
glucuronidase (GUSB) activity. The MPSVII mutation was
backcrossed onto the NOD/SCID strain, and human CD34+
cells engraft in the resultant NOD/SCID/MPSVII strain to
levels equivalent to the NOD/SCID parent [83]. Tissue
slides prepared from this strain allow rapid visualization of
human cells which carry normal levels of GUSB, against
the background mouse tissues which are null for the
enzyme (Fig. 2). Following the enzymatic reaction, slides
can be counterstained with antibodies to a tissue-specific
protein marker. The enzymatic stain is quite specific, and,
although the released enzyme can be taken up by
neighboring cells, it is in a processed form no longer
detectable by the histochemical analysis. Thus, the individ-
ual transplanted human cells stand out vividly against the
background GUSB-null murine tissues (Fig. 2). Most
notably, human cells expressing GUSB can be detected
without reliance on the expression of cell surface markers.
This is important in tissue repair studies in hypoxic
environments, where the phenotype of homed stem cells
can be dramatically different from that of the transplanted
population. The use of the GUSB enzyme staining to detect
human cells in NOD/SCID MPSVII mice is proving to be
more fast and efficient than FISH, although we and others
do still use Y chromosome and centromeric FISH for
verification of antibody and enzymatic staining methods
(Fig. 1).
Because donor cell surface protein expression can be
altered in nonhematopoietic tissues due to cell fusion or
other mechanisms, we used the NOD/SCID/MPSVII model
to study the tissue distribution of ALDH
hiLin
− vs. ALDH-
loLin
− cells in liver repair. Injection of the ALDH
loLin
−
population, which contains committed progenitors but not
stem cells, did not produce significant human cell engraft-
ment in any tissue. In contrast, injection of 2–4×10
5
ALDH
hiLin
− cells into sublethally irradiated (300 cGy)
NOD/SCID/MPSVII mice demonstrated high levels of
hematopoietic cell engraftment in the BM (70.5±15.1%),
spleen (7.0±2.8%), and peripheral blood (17.0±10.7%).
Significant human engraftment was also detected, with
single cell sensitivity, in nonhematopoietic tissues (liver,
pancreas, kidney, lung, heart, skeletal muscle, and brain) of
mice transplanted with the ALDH
hiLin
− cells. An example
of the specificity of locating transplanted human cells in
murine tissue sections is shown in Fig. 2. GUSB activity
was colocalized with CD45 expression in the BM of mice
transplanted with ALDH
hiLin
− cells. Histochemical stain-
ing confirmed the presence of GUSB+ cells that did not
express human CD45 and had hepatocyte morphology [84].
These hepatocyte-like GUSB+ cells were also present after
the transplantation of the more purified ALDH
hiCD133
+Lin
− subpopulation, which is greatly enriched for human
stem cells [44]. In the pancreas, GUSB+ donor cells were
localized in ductal regions and surrounding recipient islets.
The ALDH
hiLin
− UCB cells demonstrated a previously
uncharacterized high level of engraftment in nonhemato-
poietic organs of NOD/SCID MPSVII mice [84]. We next
investigated cellular fusion and nuclear reprogramming as a
putative mechanism for the production of nonhematopoietic
murine cells expressing donor human cell-derived GUSB
and albumin.
Gene transfer from donor to recipient cell can potentially
occur through fusion, as elegantly demonstrated by other
groups in liver [12, 13, 16, 22] and muscle [85]. We
wondered whether cell fusion was playing a major role in
the tissue repair that we were observing to be mediated by
the different human stem cell populations. We used FISH to
assess human cells in the damaged livers of immune-
deficient mice, using probes for human ALU repeats [79].
This technique proved to be sensitive enough to detect
human albumin-expressing hepatocyte-like cells in the
heavily damaged mouse livers, and all human albumin-
expressing binucleate cells had human DNA expression in
both nuclei [79]. However, this technique did not rule out
the possible presence of murine DNA in the same cells,
which would be a demonstration of fusion.
To examine the issue of fusion in a more detailed
manner, we performed a further series of studies that
Semin Immunopathol (2009) 31:411–419 415examined the contribution of human umbilical-cord-blood-
derived stem cells (hCBSC) to liver repair. The frequency
of hCBSC-derived hepatocytes varies tremendously be-
tween different studies and it is still controversial as to
whether hCBSC-derived cells can transdifferentiate into
hepatocytes or simply fuse to recipient hepatocytes. We
used the GUSB-deficient NOD/SCID/MPSVII mouse
model for better identification of engrafted cells. We
transplanted lineage-depleted human umbilical-cord-
blood-derived cells that had been isolated on the basis
of high aldehyde dehydrogenase activity (ALDH
hiLin
−)
into irradiated NOD/SCID/MPSVII mice followed by
carbon tetrachloride administration to induce liver damage.
We found that the ALDH
hiLin
− cells engrafted efficiently
into the recipient mouse livers and that they improved
recovery of the mice from toxic insult. The percentage of
human cells in these livers ranged between 3% and 14.2%
using quantitative real-time polymerase chain reaction.
Human cells expressing liver-specific α-1-antitrypsin
mRNA, albumin, and hepatocyte nuclear factor 1 protein
were detected in the recipient livers [86]. Interestingly,
human vs. murine centromeric fluorescent in situ hybrid-
ization analysis on the liver sections demonstrated that most
human cells were not fused to murine cells (Fig. 1).
However, the majority of the rarer human-originated
albumin-expressing cells did also carry mouse genetic
material and therefore were the product of cell fusion.
We have previously shown that highly purified CD34
+CD38−CD7− human cord blood stem cells with known
potent hematopoietic potential could give rise to
hepatocyte-like cells in immunodeficient mice [79]. How-
ever, the frequency of hepatocyte-like cells derived from
hematopoietic cells in mouse models is rare [21]. The
mechanisms responsible for these phenomena are also still
somewhat controversial. Both direct transdifferentiation
[18, 87, 88] of bone marrow and umbilical-cord-blood-
derived stem cells to hepatocytes and fusion between
BMSC-derived cells and recipient hepatocytes have been
reported [12, 13, 15, 22, 89–91]. In our most recent studies,
limited numbers (0.05%) of hepatocyte-like cells derived
from CBSCs were detected in the recipient livers while
significant numbers of donor cells, mostly hematopoietic,
were engrafted to the liver following damage. Similar low
frequencies of bone-marrow-derived hepatocytes were
reported by others [21] and thus represent an obstacle to
clinical application.
However, CBSC-derived cells may contribute indirectly
to liver regeneration. Hematopoietic cells are capable of
producing cytokines, such as interleukin 6, tumor necrosis
factor alpha, HGF, and others, to stimulate hepatocyte
proliferation [92, 93]. It has also been reported that
BMSCs can partially repair CCl4-induced fibrosis of the
mouse liver through the activation of metalloproteinase-9
[94]. In agreement with those data, we observed signifi-
cantly higher levels of survival in the mice that had been
transplanted with human ALDH
hiLin
− stem cells in
comparison to nontransplanted controls and those trans-
planted with ALDH
loLin
− cells, which represent commit-
ted progenitors. We conclude that human stem cells or
their progeny may home to the injured liver and release
paracrine factors that hasten ti s s u er e p a i r ,w h i l ef u s i o no f
these cells with hepatocytes occurs rarely and contributes
to a lesser extent to liver repair [86].
In summary, our data show that human bone-marrow-
and cord-blood-derived stem cells or their progeny can fuse
with host hepatocytes and that the fused cells gradually lose
human genetic material. Our most recent data demonstrate
that human albumin-expressing cells were generated from
fusion of human cord-blood-derived cells with the recipient
murine hepatocytes. The CD34+ and ALDH high stem cell
subsets from both marrow and umbilical cord blood did
however have a significant potential to repair liver through
paracrine effects, and the human ALDH high stem cells
caused a significant increase in survival of immune-
deficient mice that had been given a toxic liver insult.
Our data suggest that the primary beneficial effects from
adult stem cell transplantation to injured liver may not be
from direct generation of new hepatocytes but rather
through the reparative paracrine effects that the engrafted
stem cells exert on the damaged tissue.
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